CoChat

Onychomycosis: An Updated Review

Open access
Leung, Alexander K.C., Lam, Joseph M., Leong, Kin F., Hon, Kam L., Barankin, Benjamin, Leung, Amy A.M., Wong, Alex H.C. · 2020 · Recent Patents on Inflammation & Allergy Drug Discovery
Cited by 187

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Background : Onychomycosis is a common fungal infection of the nail. Objective: The study aimed to provide an update on the evaluation, diagnosis, and treatment of onychomycosis. Methods: A PubMed search was completed in Clinical Queries using the key term “onychomycosis”. The search was conducted in May 2019. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews published within the past 20 years. The search was restricted to English literature. Patents were searched using the key term “onychomycosis” in www.freepatentsonline.com. Results : Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. The diagnosis can be confirmed by direct microscopic examination with a potassium hydroxide wet-mount preparation, histopathologic examination of the trimmed affected nail plate with a periodic-acid-Schiff stain, fungal culture, or polymerase chain reaction assays. Laboratory confirmation of onychomycosis before beginning a treatment regimen should be considered. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis and is a therapeutic option when oral antifungal agents are contraindicated or cannot be tolerated. Recent patents related to the management of onychomycosis are also discussed. Conclusion: Oral antifungal therapies are effective, but significant adverse effects limit their use. Although topical antifungal therapies have minimal adverse events, they are less effective than oral antifungal therapies, due to poor nail penetration. Therefore, there is a need for exploring more effective and/or alternative treatment modalities for the treatment of onychomycosis which are safer and more effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1872213x13666191026090713

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 105

  1. Hoy N.Y.; Leung A.K.; Metelitsa A.I.; Adams S.; New concepts in median nail dystrophy, onychomycosis, and hand, foot, and mouth disease nail pathology. ISRN Dermatol 2012,2012 · doi:10.5402/2012/680163
  2. Vlahovic T.C.; Onychomycosis: Evaluation, treatment options, managing recurrence, and patient outcomes. Clin Podiatr Med Surg 2016,33(3),305-318 · doi:10.1016/j.cpm.2016.02.001
  3. Queller J.N.; Bhatia N.; The dermatologist’s approach to onychomycosis. J Fungi (Basel) 2015,1(2),173-184 · doi:10.3390/jof1020173
  4. Gupta A.K.; Mays R.R.; Versteeg S.G.; Shear N.H.; Piguet V.; Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther 2018,16(12),929-938 · doi:10.1080/14787210.2018.1544891
  5. Gupta A.K.; Sibbald R.G.; Andriessen A.; Belley R.; Boroditsky A.; Botros M.; Toenail onychomycosis - A Canadian approach with a new transungual treatment: Development of a clinical pathway. J Cutan Med Surg 2015,19(5),440-449 · doi:10.1177/1203475415581310
  6. Joyce A.; Gupta A.K.; Koenig L.; Wolcott R.; Carviel J.; Fungal diversity and onychomycosis: An analysis of 8,816 toenail samples using quantitative PCR and next-generation sequencing. J Am Podiatr Med Assoc 2019,109(1),57-63 · doi:10.7547/17-070
  7. Youssef A.B.; Kallel A.; Azaiz Z.; Jemel S.; Bada N.; Chouchen A.; Onychomycosis: Which fungal species are involved? Experience of the Laboratory of Parasitology-Mycology of the Rabta Hospital of Tunis. J Mycol Med 2018,28(4),651-654 · doi:10.1016/j.mycmed.2018.07.005
  8. Fike J.M.; Kollipara R.; Alkul S.; Stetson C.L.; Case report of onychomycosis and tinea corporis due to Microsporum gypseum. J Cutan Med Surg 2018,22(1),94-96 · doi:10.1177/1203475417724439
  9. Pang S.M.; Pang J.Y.Y.; Fook-Chong S.; Tan A.L.; Tinea unguium onychomycosis caused by dermatophytes: A ten-year (2005-2014) retrospective study in a tertiary hospital in Singapore. Singapore Med J 2018,59(10),524-527 · doi:10.11622/smedj.2018037
  10. Sato T.; Kitahara H.; Honda H.; Katsukawa F.; Hiruma M.; Yaguchi T.; Onychomycosis of the middle finger of a Japanese judo athlete due to Trichophyton tonsurans. Med Mycol J 2019,60(1),1-4 · doi:10.3314/mmj.18-00012
  11. Solís-Arias M.P.; García-Romero M.T.; Onychomycosis in children. A review. Int J Dermatol 2017,56(2),123-130 · doi:10.1111/ijd.13392
  12. Hirose M.; Noguchi H.; Yaguchi T.; Matsumoto T.; Hiruma M.; Fukushima S.; Onychomycosis caused by Aspergillus subramanianii. J Dermatol 2018,45(11),1362-1366 · doi:10.1111/1346-8138.14616
  13. Hon K.L.; Leung A.K.; Alopecia areata. Recent Pat Inflamm Allergy Drug Discov 2011,5(2),98-107 · doi:10.2174/187221311795399291
  14. Kimura U.; Hiruma M.; Kano R.; Matsumoto T.; Takamori K.; Suga Y.; Onychomycosis caused by Scopulariopsis brevicaulis: The third documented case in Japan. J Dermatol 2019,46(5),e167-e168 · doi:10.1111/1346-8138.14677
  15. Matsuyama Y.; Nakamura T.; Hagi T.; Asanuma K.; Sudo A.; Subungual onychomycosis due to Aspergillus niger mimicking a glomus tumor: A case report. Biomed Rep 2017,7(6),532-534 · doi:10.3892/br.2017.994
  16. Mohanty P.; Dash S.; Mohapatra L.; Jain M.; Total dystrophic onychomycosis due to Syncephalastrum racemosum - A rare cause and its novel treatment option. Indian Dermatol Online J 2019,10(2),171-173 · doi:10.4103/idoj.idoj_155_18
  17. Moreno G.; Arenas R.; Other fungi causing onychomycosis. Clin Dermatol 2010,28(2),160-163 · doi:10.1016/j.clindermatol.2009.12.009
  18. Noguchi H.; Hiruma M.; Miyashita A.; Makino K.; Miyata K.; Ihn H.; A case of fingernail onychomycosis due to Aspergillus flavus. Med Mycol J 2016,57(2),E21-E25 · doi:10.3314/mmj.57.e21
  19. Piraccini B.M.; Alessandrini A.; Onychomycosis: A review. J Fungi (Basel) 2015,1(1),30-43 · doi:10.3390/jof1010030
  20. Pontini P.; Gorani A.; Veraldi S.; Onychomycosis by Paecilomyces lilacinus. G Ital Dermatol Venereol 2016,151(6),706-709
  21. Pote S.T.; Khan U.; Lahiri K.K.; Patole M.S.; Thakar M.R.; Shah S.R.; Onychomycosis due to Achaetomium strumarium. J Mycol Med 2018,28(3),510-513 · doi:10.1016/j.mycmed.2018.07.002
  22. Veiga F.F.; de Castro-Hoshino L.V.; Sato F.; Bombassaro A.; Vicente V.A.; Mendes V.; Fusarium oxysporum is an onychomycosis etiopathogenic agent. Future Microbiol 2018,13,1745-1756 · doi:10.2217/fmb-2018-0245
  23. Ge G.; Yang Z.; Li D.; Sybren de Hoog G.; Shi D.; Onychomycosis with greenish-black discolorations and recurrent onycholysis caused by Candida parapsilosis. Med Mycol Case Rep 2019,24,48-50 · doi:10.1016/j.mmcr.2019.04.005
  24. Seebacher C.; Brasch J.; Abeck D.; Cornely O.; Effendy I.; Ginter-Hanselmayer G.; Onychomycosis. J Dtsch Dermatol Ges 2007,5(1),61-66 · doi:10.1111/j.1610-0387.2007.06134.x
  25. Goldstein A.O.; Bhatia N.; Onychomycosis: Epidemiology, clinical features, and diagnosis. Post TW, edUp To Date Waltham, MA. (Accessed on June 30, 2019).
  26. Cozzani E.; Agnoletti A.F.; Speziari S.; Schiavetti I.; Zotti M.; Persi A.; Epidemiological study of onychomycosis in older adults with onychodystrophy. Geriatr Gerontol Int 2016,16(4),486-491 · doi:10.1111/ggi.12496
  27. Gupta A.K.; Studholme C.; Update on efinaconazole 10% topical solution for the treatment of onychomycosis. Skin Therapy Lett 2016,21(6),7-11
  28. Rosen T.; Friedlander S.F.; Kircik L.; Zirwas M.J.; Stein Gold L.; Bhatia N.; Onychomycosis: Epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol 2015,14(3),223-233
  29. Rosen T.; Tinea and onychomycosis. Semin Cutan Med Surg 2016,35(Suppl. 6),S110-S113 · doi:10.12788/j.sder.2016.035
  30. Allevato M.A.; Diseases mimicking onychomycosis. Clin Dermatol 2010,28(2),164-177 · doi:10.1016/j.clindermatol.2009.12.001
  31. Assadamongkol R.; Lertwattanarak R.; Wannachalee T.; Bunyaratavej S.; Leeyaphan C.; Matthapan L.; Prevalence, risk factors, and type of organism in fungal foot infection and toenail onychomycosis in Thai diabetic patients. J Med Assoc Thai 2016,99(6),659-664
  32. Cathcart S.; Cantrell W.; Elewski Be.; Onychomycosis and diabetes. J Eur Acad Dermatol Venereol 2009,23(10),1119-1122 · doi:10.1111/j.1468-3083.2009.03225.x
  33. Daggett C.; Brodell R.T.; Daniel C.R.; Jackson J.; Onychomycosis in athletes. Am J Clin Dermatol 2019,20(5),691-698 · doi:10.1007/s40257-019-00448-4
  34. Gallo L.; Cinelli E.; Fabbrocini G.; Vastarella M.; A 15-year retrospective study on the prevalence of onychomycosis in psoriatic vs non-psoriatic patients: A new European shift from dermatophytes towards yeast. Mycoses 2019,62(8),659-664 · doi:10.1111/myc.12925
  35. Gómez-Moyano E.; Crespo-Erchiga V.; HIV infection manifesting as proximal white onychomycosis. N Engl J Med 2017,377(18) · doi:10.1056/nejmicm1703082
  36. Jimenez-Gonzalez C.; Mata-Marin J.A.; Arroyo-Anduiza C.I.; Ascencio-Montiel Ide J.; Fuentes-Allen J.L.; Gaytan-Martinez J.; Prevalence and etiology of onychomycosis in the HIV-infected Mexican population. Eur J Dermatol 2013,23(3),378-381 · doi:10.1684/ejd.2013.2015
  37. Shemer A.; Gupta A.K.; Amichai B.; Baum S.; Barzilai A.; Farhi R.; Increased risk of tinea pedis and onychomycosis among swimming pool employees in Netanya area, Israel. Mycopathologia 2016,181(11-12),851-856 · doi:10.1007/s11046-016-0040-5
  38. Tabassum S.; Rahman A.; Awan S.; Jabeen K.; Farooqi J.; Ahmed B.; Factors associated with onychomycosis in nail psoriasis: A multicenter study in Pakistan. Int J Dermatol 2019,58(6),672-678 · doi:10.1111/ijd.14364
  39. Grover C.; Khurana A.; Onychomycosis: Newer insights in pathogenesis and diagnosis. Indian J Dermatol Venereol Leprol 2012,78(3),263-270 · doi:10.4103/0378-6323.95440
  40. Monteagudo B.; Figueroa O.; Suárez-Magdalena O.; Méndez-Lage S.; Green nail caused by onychomycosis coinfected with Pseudomonas aeruginosa. Actas Dermosifiliogr 2019,110(9),783-785 · doi:10.1016/j.adengl.2018.04.023
  41. Akhtar N.; Sharma H.; Pathak K.; Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo) 2016,2016 · doi:10.1155/2016/1387936
  42. Gupta A.K.; Mays R.R.; Versteeg S.G.; Piraccini B.M.; Takwale A.; Shemer A.; Global perspectives for the management of onychomycosis. Int J Dermatol 2019,58(10),1118-1129 · doi:10.1111/ijd.14346
  43. Shemer A.; Update: Medical treatment of onychomycosis. Dermatol Ther 2012,25(6),582-593 · doi:10.1111/j.1529-8019.2012.01551.x
  44. Gupta A.K.; Versteeg S.G.; Shear N.H.; Confirmatory testing prior to treating toenail onychomycosis is recommended in Canada. J Cutan Med Surg 2018,22(2),244-245 · doi:10.1177/1203475417746126
  45. Li D.G.; Cohen J.M.; Mikailov A.; Williams R.F.; Laga A.C.; Mostaghimi A.; Clinical diagnostic accuracy of onychomycosis: A multispecialty comparison study. Dermatol Res Pract 2018,2018 · doi:10.1155/2018/2630176
  46. Nirmal B.; Utility of a multispectral dermatoscope in onychomycosis. Indian J Dermatol 2018,63(1),87-88 · doi:10.4103/ijd.ijd_37_17
  47. Bodman M.A.; Point-of-care diagnosis of onychomycosis by dermoscopy. J Am Podiatr Med Assoc 2017,107(5),413-418 · doi:10.7547/16-183
  48. De Crignis G.; Valgas N.; Rezende P.; Leverone A.; Nakamura R.; Dermatoscopy of onychomycosis. Int J Dermatol 2014,53(2),e97-e99 · doi:10.1111/ijd.12104
  49. Nargis T.; Pinto M.; Shenoy M.M.; Hegde S.; Dermoscopic features of distal lateral subungual onychomycosis. Indian Dermatol Online J 2018,9(1),16-19 · doi:10.4103/idoj.idoj_40_17
  50. Bertanha L.; Chiacchio N.D.; Nail clipping in onychomycosis. An Bras Dermatol 2016,91(5),688-690 · doi:10.1590/abd1806-4841.20164968
  51. Bet D.L.; Reis A.L.; Di Chiacchio N.; Belda W.; Dermoscopy and onychomycosis: Guided nail abrasion for mycological samples. An Bras Dermatol 2015,90(6),904-906 · doi:10.1590/abd1806-4841.20154615
  52. Kandi V.; Tungiasis presenting as onychomycosis: Probably the first report of flea infestation of the nail observed using modified potassium hydroxide mount technique. Cureus 2018,10(3) · doi:10.7759/cureus.2278
  53. Leung A.K.; Robson W.L.; Hair loss in children. J R Soc Health 1993,113(5),252-256 · doi:10.1177/146642409311300509
  54. Leung A.K.; Lam J.M.; Leong K.F.; Sergi C.M.; Melanonychia striata: Clarifying behind the black curtain. A review of clinical evaluation and management of the 21 century. Int J Dermatol 2019,58(11),1239-1245 · doi:10.1111/ijd.14464
  55. Oztürk Durmaz E.; Sezer E.; Dikicioğlu Çetin E.; Sahin S.; Onychomatricoma masquerading as candidal onychomycosis and paronychia. Acta Dermatovenerol Croat 2013,21(3),198-201
  56. Goldstein A.O.; Bhatia N.; Onychomycosis: Management. Post TW, ed UpToDate Waltham, MA. (Accessed on June 30, 2019).
  57. Ocampo-Garza J.; Di Chiacchio N.G.; Di Chiacchio N.; Machado-Filho C.D.; Acute transverse overcurvature of the nail due to onychomycosis. J Eur Acad Dermatol Venereol 2017,31(4),e202-e203 · doi:10.1111/jdv.13955
  58. Hanna S.; Andriessen A.; Beecker J.; Gilbert M.; Goldstein E.; Kalia S.; Clinical insights about onychomycosis and its treatment: A consensus. J Drugs Dermatol 2018,17(3),253-262
  59. Gupta A.K.; Paquet M.; Systemic antifungals to treat onychomycosis in children: A systematic review. Pediatr Dermatol 2013,30(3),294-302 · doi:10.1111/pde.12048
  60. Gupta A.K.; Mays R.R.; Versteeg S.G.; Shear N.H.; Friedlander S.F.; Onychomycosis in children: Safety and efficacy of antifungal agents. Pediatr Dermatol 2018,35(5),552-559 · doi:10.1111/pde.13561
  61. de Sá D.C.; Lamas A.P.; Tosti A.; Oral therapy for onychomycosis: An evidence-based review. Am J Clin Dermatol 2014,15(1),17-36 · doi:10.1007/s40257-013-0056-2
  62. Yadav P.; Singal A.; Pandhi D.; Das S.; Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol 2015,81(4),363-369 · doi:10.4103/0378-6323.158634
  63. Faergemann J.; Anderson C.; Hersle K.; Hradil E.; Nordin P.; Kaaman T.; Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995,32(5 Pt 1),750-753 · doi:10.1016/0190-9622(95)91454-4
  64. Dhamoon R.K.; Popli H.; Gupta M.; Novel drug delivery strategies for the treatment of onychomycosis. Pharm Nanotechnol 2019,7(1),24-38 · doi:10.2174/2211738507666190228104031
  65. Piraccini B.M.; Tosti A.; Ciclopirox hydroxypropyl chitosan: Efficacy in mild-to-moderate onychomycosis. Skin Appendage Disord 2018,5(1),13-19 · doi:10.1159/000488606
  66. Canavan T.N.; Bevans S.L.; Cantrell W.C.; Wang C.; Elewski B.E.; Single-center, prospective, blinded study comparing the efficacy and compatibility of efinaconazole 10% solution in treating onychomycosis with and without concurrent nail polish use. Skin Appendage Disord 2018,5(1),9-12 · doi:10.1159/000488369
  67. Zeichner J.A.; Stein Gold L.; Korotzer A.; Penetration of ((14)C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polish. J Clin Aesthet Dermatol 2014,7(9),34-36
  68. Aly R.; Gupta A.K.; Winter T.; Zane L.T.; Vlahovic T.; Tavaborole in difficult-to-treat onychomycosis cases: A post-hoc assessment of Phase III subjects. J Drugs Dermatol 2017,16(10),1016-1021
  69. Krasaeath R.; Elizondo J.; Topical antifungals for treatment of onychomycosis. Am Fam Physician 2016,94(9),734
  70. Rich P.; Spellman M.; Purohit V.; Zang C.; Crook T.J.; Tavaborole 5% topical solution for the treatment of toenail onychomycosis in pediatric patients: Results from a Phase 4 open-label study. J Drugs Dermatol 2019,18(2),190-195
  71. Feng X.; Xiong X.; Ran Y.; Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review. Dermatol Ther 2017,30(3) · doi:10.1111/dth.12457
  72. Eichenfield L.F.; Friedlander S.F.; Pediatric onychomycosis: The emerging role of topical therapy. J Drugs Dermatol 2017,16(2),105-109
  73. Feldstein S.; Totri C.; Friedlander S.F.; Antifungal therapy for onychomycosis in children. Clin Dermatol 2015,33(3),333-339 · doi:10.1016/j.clindermatol.2014.12.010
  74. Gupta A.K.; Foley K.A.; Versteeg S.G.; Lasers for onychomycosis. J Cutan Med Surg 2017,21(2),114-116 · doi:10.1177/1203475416677722
  75. Abd El-Aal E.B.; Abdo H.M.; Ibrahim S.M.; Eldestawy M.T.; Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis. J Dermatolog Treat 2019,30(3),277-282 · doi:10.1080/09546634.2018.1509046
  76. Bonhert K.; Dorizas A.; Sadick N.S.; Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd: YAG laser for treatment of toenail onychomycosis. J Cosmet Laser Ther 2019,21(3),179-183 · doi:10.1080/14764172.2018.1502451
  77. do Espírito Santo R.B.; Deps P.D.; Case study of onychomycosis patients treated with 1,064-nm Nd: YAG laser. Case Rep Dermatol 2018,10(2),216-225 · doi:10.1159/000492526
  78. Francuzik W.; Fritz K.; Salavastru C.; Laser therapies for onychomycosis - Critical evaluation of methods and effectiveness. J Eur Acad Dermatol Venereol 2016,30(6),936-942 · DOI
  79. Khater M.H.; Khattab F.M.; Combined long pulsed Nd-Yag laser and itraconazole versus itraconazole alone in the treatment of onychomycosis nails. J Dermatolog Treat 2019,3,1-19 · doi:10.1080/09546634.2019.1623861
  80. Okan G.; Tarikci N.; Gokdemir G.; The effect of long-pulsed Nd: YAG laser for the treatment of onychomycosis. J Am Podiatr Med Assoc 2017,107(1),54-59 · doi:10.7547/15-137
  81. Piccolo D.; Kostaki D.; Del Duca E.; Cannarozzo G.; Sannino M.; Nisticò S.; Long-pulsed 1064-nm Nd: YAG laser for the treatment of onychomycosis. Photomed Laser Surg 2017,35(4),213-216 · doi:10.1089/pho.2016.4153
  82. Rivers J.K.; Vestvik B.J.; Berkowitz J.; Real-world efficacy of 1064-nm Nd: YAG laser for the treatment of onychomycosis. J Cutan Med Surg 2017,21(2),108-113 · doi:10.1177/1203475416676804
  83. Weber G.C.; Firouzi P.; Baran A.M.; Bölke E.; Schrumpf H.; Buhren B.A.; Treatment of onychomycosis using a 1064-nm diode laser with or without topical antifungal therapy: A single-center, retrospective analysis in 56 patients. Eur J Med Res 2018,23(1),53 · doi:10.1186/s40001-018-0340-y
  84. Wiznia L.E.; Quatrano N.A.; Mu E.W.; Rieder E.A.; A clinical review of laser and light therapy for nail psoriasis and onychomycosis. Dermatol Surg 2017,43(2),161-172 · doi:10.1097/dss.0000000000000841
  85. Zawar V.; Sarda A.; De A.; Clearance of recalcitrant onychomycosis following Q-switched Nd-Yag laser. J Cutan Aesthet Surg 2017,10(4),226-227 · doi:10.4103/jcas.jcas_18_17
  86. Zhou B.R.; Lu Y.; Permatasari F.; Huang H.; Li J.; Liu J.; The efficacy of fractional carbon dioxide (CO) laser combined with luliconazole 1% cream for the treatment of onychomycosis: A randomized, controlled trial. Medicine (Baltimore) 2016,95(44) · doi:10.1097/md.0000000000005141
  87. Gupta A.K.; Versteeg S.G.; A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. J Eur Acad Dermatol Venereol 2017,31(7),1111-1118 · doi:10.1111/jdv.14212
  88. El-Tatawy R.A.; Aliweh H.A.; Hegab D.S.; Talaat R.A.Z.; Shams Eldeen M.A.; Fractional carbon dioxide laser and topical tioconazole in the treatment of fingernail onychomycosis. Lasers Med Sci 2019,34(9),1873-1880 · doi:10.1007/s10103-019-02789-2
  89. Morgado L.F.; Trávolo A.R.F.; Muehlmann L.A.; Narcizo P.S.; Nunes R.B.; Pereira P.A.G.; Photodynamic therapy treatment of onychomycosis with aluminium-phthalocyanine chloride nanoemulsions: A proof of concept clinical trial. J Photochem Photobiol B 2017,173,266-270 · doi:10.1016/j.jphotobiol.2017.06.010
  90. Alberdi E.; Gómez C.; Efficiency of methylene blue-mediated photodynamic therapy vs. intense pulsed light in the treatment of onychomycosis in the toenails. Photodermatol Photoimmunol Photomed 2019,35(2),69-77 · doi:10.1111/phpp.12420
  91. Bhatta A.K.; Keyal U.; Wang X.L.; Photodynamic therapy for onychomycosis: A systematic review. Photodiagn Photodyn Ther 2016,15,228-235 · doi:10.1016/j.pdpdt.2016.07.010
  92. Bristow I.; Baran R.; Score M.; Rapid treatment of subungual onychomycosis using controlled micro nail penetration and terbinafine solution. J Drugs Dermatol 2016,15(8),974-978
  93. Shemer A.; Gupta A.K.; Babaev M.; Barzilai A.; Farhi R.; Daniel Iii C.R.; A retrospective study comparing K101 nail solution as a monotherapy and in combination with oral terbinafine or itraconazole for the treatment of toenail onychomycosis. Skin Appendage Disord 2018,4(3),166-170 · doi:10.1159/000484211
  94. Repka M.A.; Mididoddi P.K.; Stodghill S.P.; Influence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm 2004,282(1-2),95-106 · doi:10.1016/j.ijpharm.2004.06.010
  95. Kushwaha A.; Shivakumar H.N.; Murthy S.N.; Iontophoresis for drug delivery into the nail apparatus: Exploring hyponychium as the site of delivery. Drug Dev Ind Pharm 2016,42(10),1678-1682 · doi:10.3109/03639045.2016.1165690
  96. Lipner S.R.; Scher R.K.; Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol 2015,14(5),492-494
  97. Scher R.K.; Tosti A.; Joseph W.S.; Vlahovic T.C.; Plasencia J.; Markinson B.C.; Onychomycosis diagnosis and management: Perspectives from a joint dermatology-podiatry roundtable. J Drugs Dermatol 2015,14(9),1016-1021
  98. Shemer A; Gupta AK; Kamshov A; Babaev M; Farhi R; Daniel CR; Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure Dermatol Ther 30(5).2017 · doi:10.1111/dth.12545
  99. Tosti A.; Elewski B.E.; Onychomycosis: Practical approaches to minimize relapse and recurrence. Skin Appendage Disord 2016,2(1-2),83-87 · doi:10.1159/000448056
  100. Kemna M.E.; Elewski B.E. A U.S.; epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996,35(4),539-542 · doi:10.1016/s0190-9622(96)90675-1
  101. Al-Hatmi A.M.; Bonifaz A.; Calderón L.; Curfs-Breuker I.; Meis J.F.; van Diepeningen A.D.; Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole. Br J Dermatol 2015,173(1),253-255 · doi:10.1111/bjd.13589
  102. Lipner S.R.; Friedman G.; Scher R.K.; Pilot study to evaluate a plasma device for the treatment of onychomycosis. Clin Exp Dermatol 2017,42(3),295-298 · doi:10.1111/ced.12973
  103. Heinlin J.; Maisch T.; Zimmermann J.L.; Shimizu T.; Holzmann T.; Simon M.; Heider J.; Contact-free inactivation of Trichophyton rubrum and Microsporum canis by cold atmospheric plasma treatment. Future Microbiol 2013,8(9),1097-1106 · doi:10.2217/fmb.13.86
  104. Sonthalia S.; Jakhar D.; Yadav P.; Kaur I.; Chemical peeling as an innovative treatment alternative to oral antifungals for onychomycosis in special circumstances. Skin Appendage Disord 2019,5(3),181-185 · doi:10.1159/000495152
  105. Krainbring V.G.A.; Composition for treating onychomycosis.WO2019105793 (2019). · DOI

Metadata

Authors
Leung, A. K. C., Lam, J. M., Leong, K. F., Hon, K. L., Barankin, B., Leung, A. A. M., & Wong, A. H. C.
Venue
Recent Patents on Inflammation & Allergy Drug Discovery
Published
2020-03-30
Volume
14
Issue
1
Pages
32-45
ISSN
1872-213X (ISSN-L)
OpenAlex
W2983564427
Cited by
187
References
60
FWCI
7.78
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Onychomycosis: An Updated Review. https://app.cochat.ai/papers/10.2174/1872213x13666191026090713
The paper
Leung, A. K. C., Lam, J. M., Leong, K. F., Hon, K. L., Barankin, B., Leung, A. A. M., & Wong, A. H. C. (2020). Onychomycosis: An Updated Review. Recent Patents on Inflammation & Allergy Drug Discovery. https://doi.org/10.2174/1872213x13666191026090713

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.